**3.6 The BLINCK algorithm**

The BLINCK algorithm has been conceived to recognize malignant lesions, especially nodular melanoma, as this tumor regularly needs customary dermatoscopic highlights. It can likewise be utilized for non-melanocytic lesions [46]. **Table 5** summarizes the evaluation operation of the BLINCK algorithm. Clues to malignancy are: atypical network, segmental streaks, irregular black dots/globules/clods, eccentric structureless zone, irregular blue or gray color, polymorphous/arborising/glomerular vessels, and parallel ridge pattern or diffuse irregular brown/black pigmentation in acral lesion. A score of ≥2 requires biopsy.

#### **3.7 TADA**

TADA is an acronym for Triage Amalgamated Dermoscopic Algorithm. TADA does not require a determination to be made to choose if the lesion ought to be extracted or alluded to a specialist [47]. TADA is accounted for to have sensitivity 94.8% and specificity 72.3% for malignant skin lesions. The first step is to determine whether the lesion has features of: angioma, dermatofibroma, and/or seborrhoeic keratosis. If yes, exclude from further analysis. If no, is there any architectural disorder? If there is architectural disorder, does the lesion have one or more of the following six predictive factors?: starburst pattern, blue-black or gray structures, shiny white structures, negative network, ulcer/erosion, and/or vessels. If yes, consider excision or refer. If no, the lesion is likely to be benign. Any doubt, follow-up or refer.
